Kipp Andrew Weiskopf, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Phagocytosis | 17 | 2024 | 1530 | 1.640 |
Why?
|
Macrophages | 14 | 2024 | 5802 | 1.460 |
Why?
|
Antibodies, Neoplasm | 4 | 2017 | 283 | 1.450 |
Why?
|
Receptors, Immunologic | 8 | 2017 | 1418 | 1.050 |
Why?
|
Antigens, CD20 | 3 | 2016 | 199 | 0.710 |
Why?
|
Antigens, Differentiation | 6 | 2017 | 921 | 0.710 |
Why?
|
Immunotherapy | 9 | 2017 | 4754 | 0.680 |
Why?
|
Myeloid Cells | 2 | 2017 | 839 | 0.480 |
Why?
|
Neoplasms | 8 | 2023 | 22371 | 0.420 |
Why?
|
Antimetabolites, Antineoplastic | 1 | 2016 | 646 | 0.410 |
Why?
|
Antibodies, Monoclonal | 9 | 2017 | 9262 | 0.380 |
Why?
|
Receptors, IgG | 1 | 2015 | 564 | 0.380 |
Why?
|
Small Cell Lung Carcinoma | 1 | 2016 | 454 | 0.370 |
Why?
|
Lung Neoplasms | 3 | 2024 | 13586 | 0.350 |
Why?
|
Antibodies, Bispecific | 3 | 2017 | 204 | 0.320 |
Why?
|
Cell Line, Tumor | 16 | 2024 | 17142 | 0.300 |
Why?
|
Adjuvants, Immunologic | 1 | 2013 | 999 | 0.290 |
Why?
|
Breast | 1 | 2016 | 1976 | 0.280 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 1 | 2016 | 1437 | 0.270 |
Why?
|
Hematopoietic Stem Cells | 2 | 2016 | 3409 | 0.240 |
Why?
|
Protein Engineering | 3 | 2016 | 553 | 0.220 |
Why?
|
Phosphatidylinositols | 1 | 2023 | 280 | 0.200 |
Why?
|
Animals | 29 | 2024 | 169285 | 0.190 |
Why?
|
Mice | 21 | 2024 | 82049 | 0.180 |
Why?
|
Molecular Targeted Therapy | 3 | 2024 | 2830 | 0.180 |
Why?
|
Xenograft Model Antitumor Assays | 7 | 2017 | 3612 | 0.170 |
Why?
|
Adenocarcinoma | 1 | 2016 | 6395 | 0.160 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 2 | 2024 | 1767 | 0.140 |
Why?
|
Cardiology Service, Hospital | 1 | 2019 | 242 | 0.140 |
Why?
|
MAP Kinase Signaling System | 1 | 2024 | 1495 | 0.140 |
Why?
|
Mastitis | 1 | 2016 | 42 | 0.130 |
Why?
|
Burkitt Lymphoma | 1 | 2017 | 338 | 0.120 |
Why?
|
Salmonella Infections | 1 | 2016 | 172 | 0.120 |
Why?
|
Salmonella typhi | 1 | 2016 | 200 | 0.120 |
Why?
|
Antibodies, Anti-Idiotypic | 1 | 2016 | 355 | 0.120 |
Why?
|
Nobel Prize | 1 | 2014 | 46 | 0.120 |
Why?
|
RNA-Directed DNA Polymerase | 1 | 2014 | 223 | 0.110 |
Why?
|
Receptors, Interleukin-2 | 1 | 2015 | 564 | 0.110 |
Why?
|
Vaccines, Synthetic | 1 | 2016 | 622 | 0.110 |
Why?
|
Tumor Escape | 1 | 2016 | 372 | 0.110 |
Why?
|
Antibodies, Monoclonal, Murine-Derived | 2 | 2013 | 696 | 0.100 |
Why?
|
Patient Admission | 1 | 2019 | 1365 | 0.100 |
Why?
|
Retroviridae | 1 | 2014 | 846 | 0.100 |
Why?
|
Directed Molecular Evolution | 1 | 2013 | 165 | 0.100 |
Why?
|
Erythropoietin | 1 | 2016 | 718 | 0.100 |
Why?
|
Dogs | 1 | 2016 | 3845 | 0.100 |
Why?
|
Infusions, Intravenous | 1 | 2016 | 2230 | 0.090 |
Why?
|
Antigen Presentation | 1 | 2017 | 1251 | 0.090 |
Why?
|
Cathepsins | 1 | 2012 | 243 | 0.090 |
Why?
|
Diabetes Mellitus, Experimental | 1 | 2017 | 1124 | 0.090 |
Why?
|
Organ Size | 1 | 2016 | 2267 | 0.090 |
Why?
|
Histocompatibility Antigens Class I | 1 | 2017 | 1361 | 0.090 |
Why?
|
Tissue Scaffolds | 1 | 2017 | 951 | 0.090 |
Why?
|
Green Fluorescent Proteins | 1 | 2016 | 2065 | 0.090 |
Why?
|
California | 1 | 2014 | 1438 | 0.090 |
Why?
|
Centrioles | 1 | 2010 | 80 | 0.090 |
Why?
|
Antibodies | 3 | 2015 | 2421 | 0.090 |
Why?
|
Macrophage Activation | 1 | 2013 | 557 | 0.090 |
Why?
|
Humans | 30 | 2024 | 768171 | 0.090 |
Why?
|
Lymphoma, Non-Hodgkin | 2 | 2015 | 1375 | 0.080 |
Why?
|
Calreticulin | 1 | 2010 | 115 | 0.080 |
Why?
|
Melanoma | 2 | 2020 | 5706 | 0.080 |
Why?
|
Neuroendocrine Tumors | 1 | 2016 | 657 | 0.080 |
Why?
|
Academic Medical Centers | 1 | 2019 | 2785 | 0.080 |
Why?
|
Proto-Oncogene Proteins c-kit | 1 | 2013 | 725 | 0.080 |
Why?
|
Drug Resistance, Neoplasm | 2 | 2014 | 5341 | 0.080 |
Why?
|
Cancer Vaccines | 1 | 2016 | 1040 | 0.080 |
Why?
|
Interleukin-2 | 1 | 2015 | 1895 | 0.080 |
Why?
|
Drug Industry | 1 | 2014 | 791 | 0.070 |
Why?
|
Leiomyosarcoma | 1 | 2012 | 426 | 0.070 |
Why?
|
Immunoglobulin G | 2 | 2016 | 4568 | 0.070 |
Why?
|
Cell Lineage | 1 | 2016 | 2575 | 0.070 |
Why?
|
Gastrointestinal Stromal Tumors | 1 | 2013 | 617 | 0.070 |
Why?
|
Lymphoma | 1 | 2016 | 1898 | 0.070 |
Why?
|
Drug Discovery | 1 | 2014 | 1068 | 0.070 |
Why?
|
History, 20th Century | 1 | 2014 | 2766 | 0.070 |
Why?
|
Killer Cells, Natural | 2 | 2014 | 2211 | 0.070 |
Why?
|
Wound Healing | 1 | 2017 | 2815 | 0.070 |
Why?
|
Mice, SCID | 3 | 2017 | 2627 | 0.060 |
Why?
|
Antineoplastic Agents | 4 | 2016 | 13677 | 0.060 |
Why?
|
Signal Transduction | 3 | 2020 | 23648 | 0.060 |
Why?
|
Cell Line | 5 | 2023 | 15602 | 0.060 |
Why?
|
Fluorescent Dyes | 1 | 2012 | 1931 | 0.060 |
Why?
|
Female | 12 | 2024 | 397187 | 0.060 |
Why?
|
Healthcare Disparities | 1 | 2019 | 3415 | 0.060 |
Why?
|
Flow Cytometry | 4 | 2016 | 5902 | 0.050 |
Why?
|
Mutation | 3 | 2024 | 30237 | 0.050 |
Why?
|
Protein Binding | 4 | 2017 | 9343 | 0.050 |
Why?
|
Mice, Inbred NOD | 2 | 2017 | 1837 | 0.050 |
Why?
|
Computational Biology | 1 | 2014 | 3567 | 0.050 |
Why?
|
Cell Differentiation | 2 | 2017 | 11677 | 0.050 |
Why?
|
Piperazines | 1 | 2013 | 2554 | 0.050 |
Why?
|
Mice, Nude | 3 | 2014 | 3623 | 0.050 |
Why?
|
Health Services Accessibility | 1 | 2019 | 5520 | 0.050 |
Why?
|
Antibody-Dependent Cell Cytotoxicity | 2 | 2014 | 306 | 0.050 |
Why?
|
RNA, Messenger | 2 | 2016 | 12801 | 0.050 |
Why?
|
Colonic Neoplasms | 1 | 2013 | 2541 | 0.050 |
Why?
|
Drosophila Proteins | 1 | 2010 | 1712 | 0.050 |
Why?
|
Cytokines | 1 | 2016 | 7452 | 0.050 |
Why?
|
Kidney | 1 | 2016 | 7064 | 0.050 |
Why?
|
Liver | 1 | 2016 | 7578 | 0.040 |
Why?
|
Pyrimidines | 1 | 2013 | 3048 | 0.040 |
Why?
|
Fatty Acids, Unsaturated | 1 | 2023 | 542 | 0.040 |
Why?
|
Neoplasm Metastasis | 3 | 2016 | 4913 | 0.040 |
Why?
|
Mice, Inbred C57BL | 5 | 2017 | 22380 | 0.040 |
Why?
|
Phospholipids | 1 | 2023 | 787 | 0.040 |
Why?
|
Cell Cycle Proteins | 1 | 2010 | 3445 | 0.040 |
Why?
|
Biomedical Research | 1 | 2014 | 3463 | 0.040 |
Why?
|
Pancreatic Neoplasms | 1 | 2016 | 5442 | 0.040 |
Why?
|
Protein Structure, Tertiary | 2 | 2015 | 3772 | 0.040 |
Why?
|
Hematopoietic Stem Cell Transplantation | 1 | 2016 | 5717 | 0.040 |
Why?
|
Mice, Transgenic | 3 | 2017 | 9561 | 0.040 |
Why?
|
Up-Regulation | 2 | 2020 | 4149 | 0.040 |
Why?
|
Smoking | 1 | 2014 | 9092 | 0.040 |
Why?
|
Drug Synergism | 2 | 2012 | 1760 | 0.030 |
Why?
|
Mice, Inbred BALB C | 2 | 2017 | 6231 | 0.030 |
Why?
|
Disease Models, Animal | 2 | 2016 | 18349 | 0.030 |
Why?
|
Skin Physiological Phenomena | 1 | 2017 | 193 | 0.030 |
Why?
|
Acute-Phase Proteins | 1 | 2017 | 252 | 0.030 |
Why?
|
Receptors, Erythropoietin | 1 | 2016 | 144 | 0.030 |
Why?
|
Biomimetics | 1 | 2017 | 172 | 0.030 |
Why?
|
Gene Knock-In Techniques | 1 | 2017 | 422 | 0.030 |
Why?
|
Retinal Dehydrogenase | 1 | 2016 | 78 | 0.030 |
Why?
|
Bacterial Load | 1 | 2016 | 154 | 0.030 |
Why?
|
Tumor Cells, Cultured | 2 | 2016 | 6124 | 0.030 |
Why?
|
T-Lymphocytes | 1 | 2013 | 10266 | 0.030 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2016 | 11878 | 0.030 |
Why?
|
Heart Failure | 1 | 2019 | 11879 | 0.030 |
Why?
|
Mice, Inbred Strains | 1 | 2017 | 1769 | 0.030 |
Why?
|
STAT5 Transcription Factor | 1 | 2015 | 268 | 0.030 |
Why?
|
Leukemia-Lymphoma, Adult T-Cell | 1 | 2015 | 168 | 0.030 |
Why?
|
Transgenes | 1 | 2017 | 1016 | 0.030 |
Why?
|
Antibody Affinity | 1 | 2015 | 252 | 0.030 |
Why?
|
Surface Plasmon Resonance | 1 | 2015 | 272 | 0.030 |
Why?
|
Macaca fascicularis | 1 | 2016 | 912 | 0.030 |
Why?
|
Mice, Mutant Strains | 1 | 2016 | 1754 | 0.030 |
Why?
|
Vascular Endothelial Growth Factor Receptor-1 | 1 | 2016 | 560 | 0.030 |
Why?
|
Receptors, Fc | 1 | 2016 | 537 | 0.030 |
Why?
|
Antibodies, Blocking | 1 | 2013 | 250 | 0.030 |
Why?
|
Erythropoiesis | 1 | 2016 | 691 | 0.030 |
Why?
|
Neoplasms, Experimental | 1 | 2017 | 1230 | 0.030 |
Why?
|
Immunocompromised Host | 1 | 2017 | 863 | 0.020 |
Why?
|
Transfection | 1 | 2020 | 5756 | 0.020 |
Why?
|
Isoenzymes | 1 | 2016 | 1688 | 0.020 |
Why?
|
Microtubule-Organizing Center | 1 | 2010 | 26 | 0.020 |
Why?
|
Mammary Neoplasms, Animal | 1 | 2012 | 123 | 0.020 |
Why?
|
Survival Analysis | 2 | 2015 | 10099 | 0.020 |
Why?
|
Drug Design | 1 | 2016 | 1046 | 0.020 |
Why?
|
Spleen | 1 | 2016 | 2296 | 0.020 |
Why?
|
CD8-Positive T-Lymphocytes | 2 | 2014 | 4648 | 0.020 |
Why?
|
Cytotoxicity, Immunologic | 1 | 2013 | 1353 | 0.020 |
Why?
|
Centrosome | 1 | 2010 | 210 | 0.020 |
Why?
|
ras Proteins | 1 | 2014 | 1058 | 0.020 |
Why?
|
Cell Proliferation | 2 | 2015 | 10478 | 0.020 |
Why?
|
Middle Aged | 3 | 2019 | 223487 | 0.020 |
Why?
|
Neoplasm Transplantation | 1 | 2012 | 2014 | 0.020 |
Why?
|
Monocytes | 1 | 2017 | 2605 | 0.020 |
Why?
|
Inpatients | 1 | 2019 | 2566 | 0.020 |
Why?
|
Breast Neoplasms | 2 | 2012 | 21207 | 0.020 |
Why?
|
Health Status Disparities | 1 | 2019 | 1885 | 0.020 |
Why?
|
Recombinant Fusion Proteins | 1 | 2016 | 3740 | 0.020 |
Why?
|
Benzamides | 1 | 2013 | 1379 | 0.020 |
Why?
|
Erythrocytes | 1 | 2016 | 2418 | 0.020 |
Why?
|
Anemia | 1 | 2016 | 1514 | 0.020 |
Why?
|
Male | 4 | 2019 | 364731 | 0.020 |
Why?
|
Boston | 1 | 2019 | 9374 | 0.020 |
Why?
|
Down-Regulation | 1 | 2013 | 2939 | 0.020 |
Why?
|
Combined Modality Therapy | 1 | 2017 | 8542 | 0.020 |
Why?
|
Animals, Genetically Modified | 1 | 2010 | 1563 | 0.020 |
Why?
|
Oocytes | 1 | 2010 | 1172 | 0.020 |
Why?
|
Polymerase Chain Reaction | 1 | 2015 | 6082 | 0.020 |
Why?
|
Patient Readmission | 1 | 2019 | 3288 | 0.020 |
Why?
|
Microtubule-Associated Proteins | 1 | 2010 | 1074 | 0.020 |
Why?
|
Models, Molecular | 1 | 2015 | 5402 | 0.020 |
Why?
|
Microscopy, Fluorescence | 1 | 2012 | 2634 | 0.020 |
Why?
|
Proto-Oncogene Proteins c-myc | 1 | 2010 | 998 | 0.010 |
Why?
|
Gene Expression | 1 | 2017 | 7601 | 0.010 |
Why?
|
Neutrophils | 1 | 2017 | 3786 | 0.010 |
Why?
|
Cell Division | 1 | 2012 | 4477 | 0.010 |
Why?
|
Immunotherapy, Adoptive | 1 | 2014 | 1512 | 0.010 |
Why?
|
Neoplasm Proteins | 1 | 2016 | 3604 | 0.010 |
Why?
|
Skin | 1 | 2017 | 4505 | 0.010 |
Why?
|
Transplantation, Heterologous | 1 | 2012 | 2393 | 0.010 |
Why?
|
Cell Membrane | 1 | 2013 | 3655 | 0.010 |
Why?
|
Graft vs Host Disease | 1 | 2015 | 3049 | 0.010 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2012 | 2846 | 0.010 |
Why?
|
Mice, Knockout | 1 | 2017 | 14488 | 0.010 |
Why?
|
Proto-Oncogene Proteins | 1 | 2014 | 4528 | 0.010 |
Why?
|
Drosophila melanogaster | 1 | 2010 | 1726 | 0.010 |
Why?
|
Prognosis | 2 | 2012 | 30009 | 0.010 |
Why?
|
Treatment Outcome | 2 | 2019 | 65379 | 0.010 |
Why?
|
Head and Neck Neoplasms | 1 | 2014 | 2931 | 0.010 |
Why?
|
DNA-Binding Proteins | 1 | 2016 | 9617 | 0.010 |
Why?
|
Urinary Bladder Neoplasms | 1 | 2010 | 2195 | 0.010 |
Why?
|
Risk Assessment | 1 | 2019 | 24318 | 0.010 |
Why?
|
Time Factors | 1 | 2019 | 40220 | 0.010 |
Why?
|
Gene Expression Regulation | 1 | 2015 | 11930 | 0.010 |
Why?
|
Leukemia, Myeloid, Acute | 1 | 2010 | 3626 | 0.010 |
Why?
|
Aged, 80 and over | 1 | 2019 | 59626 | 0.010 |
Why?
|
Colorectal Neoplasms | 1 | 2014 | 6975 | 0.010 |
Why?
|
Risk Factors | 1 | 2019 | 74944 | 0.010 |
Why?
|
Retrospective Studies | 1 | 2019 | 81760 | 0.010 |
Why?
|
Aged | 1 | 2019 | 171502 | 0.000 |
Why?
|